



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Fezagepras

Chemical Properties


CAS No. : 1002101-19-0

Formula: C₁₃H₁₈O₂

Molecular Weight: 206.28

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Fezagepras (Setogepam) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions.
Targets(IC ₅₀)	GPR
In vitro	TGF- β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepam (PBI-4050; 500 μ M; 24 hours). Setogepam (PBI-4050; 250 or 500 μ M; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2].
In vivo	In type 2 diabetes eNOS-/-db/db mice, Setogepam (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1].

Solubility Information

Solubility	DMSO: 60 mg/ml (290.87 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.8478 mL	24.2389 mL	48.4778 mL
5 mM	0.9696 mL	4.8478 mL	9.6956 mL
10 mM	0.4848 mL	2.4239 mL	4.8478 mL
50 mM	0.097 mL	0.4848 mL	0.9696 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481